Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapy products for cancer. Its core programs are CAN-2409 (aglatimagene) and CAN-3110 (linoserpaturev), both designed to use engineered viruses to stimulate an anti-tumor immune response in solid tumors. The company was formed through a series of asset licenses and rebranding from Advantagene, and it now controls development and commercialization rights for its programs in major markets including the United States, Europe, and Asia. Candel has no approved products or product sales today, so its business is centered on clinical development, manufacturing readiness, and eventual commercialization planning.

13.49

13.49

— Candel Therapeutics, Inc.
%
CAN-2409 program45% Clinical-stage HSV-based immunotherapy being developed for localized prostate cancer and other solid tumors.
CAN-3110 program30% Clinical-stage HSV-based immunotherapy focused on recurrent high-grade glioma and other oncology indications.
Discovery platform15% enLIGHTEN™ platform used to generate additional HSV-based oncology candidates.
Manufacturing and development infrastructure10% Process development, clinical manufacturing, and commercialization preparation for future approved products.

Candel does not currently sell commercial products, so its near-term 'customers' are primarily clinical investigators,...

  • Clinical trial sites and investigatorsprimary

    Hospitals, clinics, and research centers that enroll patients and run CAN-2409 and CAN-3110 studies.

  • Oncologists and surgical specialistsprimary

    Physicians who would prescribe or administer the therapies if approved, especially in solid tumor indications.

  • Healthcare payorssecondary

    Private insurers and government payors that would determine reimbursement and patient access after approval.

  • Contract manufacturing organizationsprimary

    Third parties that manufacture clinical and potential commercial supply for the product candidates.

  • Research collaborators and licensing partnerssecondary

    Potential partners that may support development, commercialization, or regional expansion of the pipeline.

Candel is headquartered in the United States and is developing its programs for major markets including the U.S...

  • •Headquartered in the United States
  • •Development and commercialization rights in the United States, Europe, and Asia
  • •Future launch planning centered on U.S. commercialization first
  • •Relies on third-party manufacturing rather than owned global plants
  • •Ventagen license covers selected Latin American countries for certain products

Candel's strategy is to advance CAN-2409 and CAN-3110 through late-stage clinical development and prepare CAN-2409 for...

01
Complete late-stage clinical development of CAN-2409short-term

CAN-2409 is the most advanced asset and the main path to first commercial revenue.

02
Advance CAN-3110 in recurrent high-grade gliomashort-term

CAN-3110 broadens the pipeline and could create a second oncology franchise if data are positive.

03
Build manufacturing readinessmedium-term

Commercial viability depends on reliable biologics manufacturing and supply chain execution.

04
Expand discovery pipelinelong-term

A broader pipeline reduces dependence on a small number of clinical assets and supports long-term value creation.

Candel faces the classic risks of a clinical-stage biopharmaceutical company: it has no product revenue, a limited...

critical

Clinical development failure

The company depends on positive trial outcomes for CAN-2409 and CAN-3110 to create any commercial value.

Scope
CAN-2409, CAN-3110, and future pipeline assets
Materiality
high
critical

Regulatory approval delays or rejection

No product can be marketed without FDA and comparable foreign approvals, and the company must provide extensive safety and efficacy data.

Scope
United States, Europe, Asia
Materiality
high
high

Capital dilution and financing dependence

The company expects continued losses and will need additional financing to advance development and commercialization.

Scope
Corporate funding and shareholder dilution
Materiality
high
high

Commercial execution risk

Candel currently lacks sales, marketing, and patient support infrastructure, which could delay launch or reduce profitability.

Scope
Future product launch
Materiality
high
medium

Competitive pressure in immuno-oncology

Large pharma and multiple biotech peers are pursuing similar viral immunotherapy and other cancer approaches.

Scope
Solid tumor oncology markets
Materiality
medium
Accrued R&D expenses
Can shift quarterly operating expenses and liabilities materially
Stock-based compensation
Affects reported losses and operating expense comparability
License and collaboration accounting
Can change expense timing and future cash flow presentation
Liquidity and going-concern assessment
Important for assessing financing risk and financial statement assumptions

Calidi Biotherapeutics, Inc.

CLDI · Biological Products, (No Diagnostic Substances)

Cantargia

CANTA.ST · Health Care

GENELUX Corp

GNLX · Pharmaceutical Preparations

CG Oncology, Inc.

CGON · Biological Products, (No Diagnostic Substances)

enGene Therapeutics Inc.

ENGN · Biological Products, (No Diagnostic Substances)

Apogee Therapeutics, Inc.

APGE · Biological Products, (No Diagnostic Substances)

: 28/04/2026